Aldeyra Therapeutics (ALDX) Q4 2021 Earnings Call Transcript
ALDX earnings call for the period ending December 31, 2021.
Stay updated with breaking news from Thomas Shrader. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ALDX earnings call for the period ending December 31, 2021.
Operator Good day. Thank you for standing by, and welcome to the G1 Therapeutics Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] I would now like to turn the conference over to your host, Mr. Will Roberts. Please go ahead, sir. William Roberts -- Vice President of Investor Relations & Corporate Communications Thank you, Sarah. Good afternoon, everyone, and welcome to the G1 conference call to discuss our seco...
Operator Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions]. Following the presentation, there will be a question-and-answer session. [Operator Instructions] I would now like to hand the conference over to Ben Church, Investor Relations and Corporate Communications at Esperion. Please go ahead, sir. Benjamin Church -- Head, Corporate Communications & Investor Relations Thank you, operator. Good morning and welcome to Esperion's Second Quarter 2021 Financial Results and Company Update Conference Call. I'm Ben Church and I'm responsible for Investor Relations...
Markets BTIG analyst Thomas Shrader maintained a Hold rating on Biogen (BIIB – Research Report) on April 22. The company’s shares closed last Friday at $262.63. According to TipRanks.com, Shrader is a 4-star analyst with an average return of 18.6% and a 41.2% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics, Stoke Therapeutics, and Gain Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $304.24 average price target, which is a 16.9% upside from current levels. In a report i...
Analysts at Stifel turned bullish on Biogen Inc (NASDAQ: BIIB) for four key reasons. The firm's Thomas Shrader upgrades Biogen's stock from Hold to Buy with a price target boosted from $300 to $415. First, there have been no news reports on the "gigantic" aducanumab phase 3 trial, which started in... Read More... Don't Miss Any Updates! News Directly in Your Inbox Subscribe to: